About: Characterization of murine CEACAM1 in vivo reveals low expression on CD8(+) T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characterization of murine CEACAM1 in vivo reveals low expression on CD8(+) T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Characterization of murine CEACAM1 in vivo reveals low expression on CD8(+) T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1
Creator	Han, Jin-Hwan Issafras, Hassan Javaid, Sarah Laskey, Jason Lee, Mike Liu, Liming Loboda, Andrey Punnonen, Juha Sadekova, Svetlana Tse, Archie Angagaw, Minilik Hsieh, Suchun Mcleod, Robbie Moniz, Raymond Nath Baral, Toya O'connor, Joann
source	PMC
abstract	Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been reported to mediate both tumorigenic and anti-tumor effects in vivo. Blockade of the CEACAM1 signaling pathway has recently been implicated as a novel mechanism for cancer immunotherapy. CC1, a mouse anti-CEACAM1 monoclonal antibody (mAb), has been widely used as a pharmacological tool in preclinical studies to inform on CEACAM1 pathway biology although limited data are available on its CEACAM1 blocking characteristics or pharmacodynamic-pharmacokinetic profiles. We sought to investigate CEACAM1 expression on mouse tumor and immune cells, characterize CC1 mAb binding, and evaluate CC1 in syngeneic mouse oncology models as a monotherapy and in combination with an anti-PD-1 mAb. CEACAM1 expression was observed at high levels on neutrophils, NK cells and myeloid-derived suppressor cells (MDSCs), while the expression on tumor-infiltrating CD8+ T cells was low. Unexpectedly, rather than blocking, CC1 facilitated binding of soluble CEACAM1 to CEACAM1 expressing cells. No anti-tumor effects were observed in CT26, MBT2 or A20 models when tested up to 30 mg/kg dose, a dose that was estimated to achieve >90% target engagement in vivo. Taken together, tumor infiltrating CD8+ T cells express low levels of CEACAM1 and CC1 Ab mediates no or minimal anti-tumor effects in vivo, as a monotherapy or in combination with anti-PD-1 treatment.
has issue date	2018-10-02(xsd:dateTime)
bibo:doi	10.18632/oncotarget.26108
bibo:pmid	30349641
has license	cc-by
sha1sum (hex)	1e88d68fd702c8accc72cece9a8df345c64b0b8c
schema:url	https://doi.org/10.18632/oncotarget.26108
resource representing a document's title	Characterization of murine CEACAM1 in vivo reveals low expression on CD8(+) T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1
has PubMed Central identifier	PMC6195382
has PubMed identifier	30349641
schema:publication	Oncotarget
resource representing a document's body	covid:1e88d68fd702c8accc72cece9a8df345c64b0b8c#body_text
is schema:about of	named entity 'BIOLOGY' named entity 'ITS' named entity 'PATHWAY' named entity 'CT26' named entity 'ESTIMATED' named entity 'MONOTHERAPY' named entity 'TO INVESTIGATE' named entity 'RECENTLY' named entity 'SYNGENEIC' named entity 'A20' named entity 'TREATMENT' named entity 'NOVEL' named entity 'INFILTRATING' named entity 'LEVELS' named entity 'ONCOLOGY' named entity 'TUMOR' named entity 'IN VIVO' named entity 'IMMUNE CELLS' named entity 'MINIMAL' named entity 'ENGAGEMENT' named entity 'TESTED' named entity 'PD-1' named entity 'MODELS' named entity 'SOLUBLE' named entity 'TO INFORM' named entity 'MURINE' covid:arg/1e88d68fd702c8accc72cece9a8df345c64b0b8c named entity 'NEUTROPHILS' named entity 'COMBINATION' named entity 'DATA' named entity 'MONOCLONAL ANTIBODY' named entity 'MEDIATES' named entity 'MG%' named entity 'BINDING' named entity 'CANCER IMMUNOTHERAPY' named entity 'OBSERVED' named entity 'LOW' named entity 'BLOCKADE' named entity 'TAKEN' named entity 'AVAILABLE' named entity 'MAB' named entity 'EXPRESS' named entity 'TARGET' named entity 'NK CELLS' named entity 'MECHANISM' named entity 'LIMITED' named entity 'RATHER' named entity 'LOW EXPRESSION' named entity 'CC1' named entity 'CEACAM1' named entity 'CHARACTERIZATION' named entity 'T CELLS' named entity 'CD8' named entity 'IN VIVO' named entity 'SIGNALING PATHWAY' named entity 'A MOUSE' named entity 'CC1' named entity 'CEACAM1' named entity 'EVALUATE' named entity 'EXPRESSION' named entity 'CELLS' named entity 'MYELOID-DERIVED SUPPRESSOR CELLS' named entity 'UP TO' named entity 'T CELLS' named entity 'EFFECTS' named entity 'PHARMACODYNAMIC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software